Newly patented CRISPR nuclease exhibits high activity in various prokaryotic and eukaryotic organisms Patent now opens up ...

Emerging antiviral defense systems are expanding the conceptual and practical boundaries of genome editing. Across bacteria, archaea, and eukaryotes, hosts ...

Current Landscape of Life Sciences The life sciences sector, encompassing pharmaceuticals, biotechnology, and medical devices ...

AI is rewriting drug discovery. Recursion Pharmaceuticals and Tempus AI might be the platforms that turn early investors into ...

Baby corn, essentially unfertilized young ears of corn, is a specialty food gaining interest for its high nutrition and low ...

Stanford Medicine researchers have built CRISPR-GPT, a large language model designed to automate the full arc of gene-editing ...

A new form of CAR T kills leukemia, multiple myeloma, and sarcoma in mice, opening the door to a future off-the-shelf cancer ...

Discover how CRISPR genome editing is revolutionizing medicine. Learn the science of Cas9, current clinical trials, and the ...

Genomics (NasdaqGS:TXG) is collaborating with PerturbAI, NVIDIA, and the Allen Institute on what is described as the largest ...

Ryvu’s ONCO Prime - an integrated precision oncology discovery platform leveraging patient-driven models, engineered systems, ...

The researchers say that, to their knowledge, this is the first demonstration of programmable, site-specific integration of a ...

PerturbAI, an AI-native therapeutics company accelerating drug discovery through systems-level understanding of diseases, emerged from stealth today with the public release of the world's largest in ...